Administration of Nivolumab in Metastatic Renal Cell Cancer
Following Treatment With mTOR Inhibitors

J 2021

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors

KOPECKY, Jindrich, Ondrej KUBECEK, Tomas BUCHLER, Bohuslav MELICHAR, Alexandr POPRACH et. al.

Basic information

Original name

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors

Authors

KOPECKY, Jindrich (203 Czech Republic, guarantor), Ondrej KUBECEK (203 Czech Republic), Tomas BUCHLER (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Milada ZEMANOVA (203 Czech Republic), Jana KATOLICKA (203 Czech Republic), Igor KISS (203 Czech Republic, belonging to the institution), Jaroslav HAJEK (203 Czech Republic), Hana STUDENTOVA (203 Czech Republic) and Martina SPISAROVA (203 Czech Republic)

Edition

In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2021, 0258-851X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.406

RIV identification code

RIV/00216224:14110/21:00124182

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.21873/invivo.12593

UT WoS

000686122800008

Keywords in English

Renal cell cancer; nivolumab; mTOR inhibitor; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; systematic inflammation index

Abstract

V originále

Background/Aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. Patients and Methods: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. Results: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pretreated with everolimus. Conclusion: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.

Citovat

KOPECKY, Jindrich, Ondrej KUBECEK, Tomas BUCHLER, Bohuslav MELICHAR, Alexandr POPRACH, Milada ZEMANOVA, Jana KATOLICKA, Igor KISS, Jaroslav HAJEK, Hana STUDENTOVA and Martina SPISAROVA. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2021, vol. 35, No 5, p. 2981-2990. ISSN 0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12593.

@article{1834649,
   author = {Kopecky, Jindrich and Kubecek, Ondrej and Buchler, Tomas and Melichar, Bohuslav and Poprach, Alexandr and Zemanova, Milada and Katolicka, Jana and Kiss, Igor and Hajek, Jaroslav and Studentova, Hana and Spisarova, Martina},
   article_location = {ATHENS},
   article_number = {5},
   doi = {http://dx.doi.org/10.21873/invivo.12593},
   keywords = {Renal cell cancer; nivolumab; mTOR inhibitor; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; systematic inflammation index},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors},
   url = {https://iv.iiarjournals.org/content/35/5/2981},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1834649
AU  - Kopecky, Jindrich - Kubecek, Ondrej - Buchler, Tomas - Melichar, Bohuslav - Poprach, Alexandr - Zemanova, Milada - Katolicka, Jana - Kiss, Igor - Hajek, Jaroslav - Studentova, Hana - Spisarova, Martina
PY  - 2021
TI  - Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
JF  - In vivo
VL  - 35
IS  - 5
SP  - 2981-2990
EP  - 2981-2990
PB  - Greece : International Institute of Anticancer Research
SN  - 0258851X
KW  - Renal cell cancer
KW  - nivolumab
KW  - mTOR inhibitor
KW  - neutrophil-lymphocyte ratio
KW  - platelet-lymphocyte ratio
KW  - systematic inflammation index
UR  - https://iv.iiarjournals.org/content/35/5/2981
N2  - Background/Aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. Patients and Methods: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. Results: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pretreated with everolimus. Conclusion: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.
ER  -

KOPECKY, Jindrich, Ondrej KUBECEK, Tomas BUCHLER, Bohuslav MELICHAR, Alexandr POPRACH, Milada ZEMANOVA, Jana KATOLICKA, Igor KISS, Jaroslav HAJEK, Hana STUDENTOVA and Martina SPISAROVA. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2021, vol.~35, No~5, p.~2981-2990. ISSN~0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12593.

Detailed Information on Publication Record